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1. Introduction
In this review, we discuss the merit of splicing isoforms as a source of biomarkers for ovari‐
an cancer with a special focus on features that distinguish splice variants from global gene
expression based markers. Key examples demonstrating the usefulness of alternative splic‐
ing (AS) as markers of ovarian cancer are described.
Ovarian cancer is a low incidence cancer with high mortality rate [1]. The asymptomatic na‐
ture of this cancer and the late stage diagnosis of most tumors are the reasons for ineffective
surgery and chemotherapy [2]. In this sense, intensive research aim at increasing overall pa‐
tient survival and quality of life by providing biomarkers for 1) early detection and 2) pre‐
diction of chemotherapy response and/or suggestion of alternative strategies. CA-125 is a
glycoprotein that is usually expressed in a variety of epithelial cells and its serum level rise
up in advance ovarian cancer [3]. However, its use as an early detection marker or as a tool
to screen the general population has not been approved so far [4,5]. CA-125 level is helpful
in treatment-decision making but do not retain the capacity to improve overall survival and
quality of life [6,7]. Clearly, there is still great need for biomarkers or combination of bio‐
markers that could positively identify early ovarian cancer lesions with great certainty or in‐
crease patients’ survival.
Genome-wide mRNA profiling presents an opportunity to rapidly identify RNA markers.
Microarray platform has been applied in numerous occasions to provide gene expression
signature correlating prognosis or indicative of chemotherapy response (review in [8]).
However, the nature of the platform used to carry the experiments and the analysis methods
and sample sets makes inter-laboratory comparison very difficult and finding reliable mark‐
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ers complicated. Indeed, a meta-analysis regrouping 829 samples fails to demonstrate the
predictive power of 16 individual gene expression signatures [9]. Consequently, very few
microarray markers reached the clinic. In contrast, high-throughput protein signature based
on mass spectrometry platform appears to have much more overlap in the peaks found by
different experimental studies [10]. However, the pace by which protein biomarkers are
translated into clinical setting is relatively slow [11]. Clearly, there is a need for novel meth‐
odology to discover ovarian cancer biomarkers that can yield reliable results and produce
tests that could be quickly integrated in normal clinical setting. In this chapter, we discuss
the potential of splice variant annotations as a tool for the discovery of ovarian cancer mark‐
ers and discuss the challenges and promises of this hidden mine.
2. Pre-mRNA splicing mechanism and regulation
Transcription of messenger RNA (mRNA) is the first step of converting the DNA code into
functional proteins. This process was often seen as a linear cascade of events that include
mRNA capping [12], splicing [13], polyadenylation [14], export to the cytoplasm [15] and trans‐
lation [16] to produce a single protein. However, in reality a single pre-mRNA can produce
many mRNAs through the process of AS and this in turn lead to the production of several pro‐
teins from a single gene. Splicing is the process by which the protein coding exons (typically
hundreds of nucleotides in length) are joined together after the removal of large non-coding in‐
trons (typically thousands of nucleotides in length) to form the coding sequence. In some
genes, this process leads to one outcome and thus named constitutive (Fig. 1.) but in most cases
it leads to more than one outcome and thus called alternative (Fig. 2). Both processes are medi‐
ated by the spliceosome, specialized machinery that recognizes consensus RNA sequences
[13,17]. The spliceosome component U1snRNP binds the 5’ splice site (5’ss), the splicing Factor
1 (SF1) binds the branch point site (BPS) adenine, U2 auxiliary factor 65 kDa subunit (U2AF65)
binds the poly-pyrimidine tract (PPT) and U2 auxiliary factor 35 kDa subunits (U2AF35) binds
the 3’ splice site (3’ss) (Fig. 1A). The last two component are further replaced by U2snRNP and
following complex base-paring rearrangements and RNA-protein interactions involving hun‐
dreds of protein, the spliced mRNA, the intron by-product and the spliceosome component are
release [17]. Chemically speaking, the splicing reaction proceeds in two trans-esterification
steps (Fig. 1B). The first step involved the attack by the 2’ hydroxyl of the branch point adenine
on the phosphate at the 5’ss, releasing at the same time the 3’end of the mRNA. The second step
involved the attack by one of the hydroxyl of the terminal phosphate on the phosphate at the
3’ss, liberating the intron in the form of a lariat. This cycle of spliceosome assembly/disassem‐
bly is repeated for every intron of a gene on the nascent RNA transcript [18].
When the splice site for some exons become weak or introns with suboptimal sequence exist
splicing may become less accurate and may depend on the factors that influence the splicing of
competing exons and consequently produce mRNA versions with different exon pairs. AS af‐
fected the majority of multi-exons genes and is believed to be the principal driver of proteome
diversity [19]. As illustrated in figure 2, two 5’ss can compete for a single 3’ss or inversely, two
3’ss can compete for a single 5’ss. These type of alternative splicing events (ASEs) are referred
to alternative 5’ (alt5’, Fig. 2A) and alternative 3’ (alt3’ Fig. 2B), respectively. The most frequent
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type of ASE in human is the full skipping of an exon (cassette exon, Fig. 2C). Some exons are al‐
so skipped as a bloc (multiple cassette exon, Fig. 2D) or mutually exclusive (Fig. 2E). AS could
also be coupled to others regulatory mechanisms such as polyadenylation [14] (Fig. 2F). In this
case, the resulting mRNA exhibits a different 3’ untranslated region (UTR), which is further
subjected to different regulation by small non-coding RNA (e.g. microRNA). In about 1 out of 3
cases, AS decision introduces a sequence containing premature stop codon [20]. In these cases,
the resulting mRNA is flagged to be degraded by the non-sense mediated decay machinery
creating an efficient mechanism that control gene expression post-transcriptionally [21] (Fig.
2G). In some cases, ASE occurs outside the coding region and influence regulatory sequence in
the UTR [22]. These different forms of splicing isoforms should not be confused with those gen‐
erated by alternative transcription start site where a single gene might transcribe from differ‐
ent promoters (Fig. 2H). In this case, and unlike alternative splicing, there is little chance that
the isoform will have different protein sequence unless a new protein-coding exon is added in
frame for translation initiation.
Figure 1. Constitutive splicing. A) Consensus splicing sequences. The 5’ss, BPS, PPT and 3’ss are represented and are
binds by U1 snRNP, SF1, U2AF65 and U2AF35, respectively. B) Splicing reaction. The first step involved the attack by
the 2’ hydroxyl of the branch point adenine on the phosphate at the 5’ss, releasing at the same time the 3’end of the
mRNA. The second step involved the attack by one of the hydroxyl of the terminal phosphate on the phosphate at the
3’ss, liberating the intron in the form of a lariat.
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Figure 2. Alternative splicing may take many different forms. A) Alt5’. B) Alt3’. C) Cassette exon. D) Multiple cassette
exons. E) Mutually exclusive exons. F) Coupled to alternative polyadenylation. G) Coupled to NMD. H) Alternative tran‐
scription initiation. Gray boxes = constitutive exons; white boxes = alternative exons; 5’ = 5’ splice site; 3’ = 3’ splice
site; A = polyadenylation site.
ASEs are normally associated with low sequence conservation near the splice site and instead
are usually linked to RNA binding motifs that may enhance or repress exon inclusion [23,24].
Motifs that enhance exon inclusion often recruit splicing factors like the SR protein family,
which in turn interact with the spliceosome via an arginine serine rich domain to increase weak
5’ss and 3’ss recognition [25] (Fig. 3A). On the other hand, splicing motifs that promotes exon
exclusion by binding members of the hnRNP family oligomerized through exon [26], block
UsnRNA recruitment [27] or loop out the alternative exon [28] (Fig. 3B to D). Similarly, se‐
quence motifs in intron may bind to SR or hnRNP proteins to influence splicing, but in this case,
the SR proteins results in exon exclusion and hnRNP in exon inclusion. This is most likely be‐
cause hnRNPs define intronic region and SR protein define exons location. Usually, these dif‐
ferent enhancers and repressor protein families work together to define the final outcome of
any ASEs (Fig. 3E) [29,30]. One of the most conserved intronic motif downstream of alternative
exons is the UGCAUG motif [31,32], which bind the tissue-specific splicing factors family
RBFOX. In general it is suggested that tissues specific splicing factors favor exon inclusion
when bound to introns downstream of alternative exons and exclusion when bound upstream.
This rule is beginning to be appreciated for several splicing factor such as Celf [33], epithelial-
specific regulatory protein [34], Nova [35] and RBFOX [36] (Fig. 3F).
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Figure 3. Schematic representation of the different mechanisms regulating alternative splicing. A) SR protein bind to
exonic splicing enhancer (ESE) and favor exon inclusion by recruting U1snRNP to 5’ss or U2 snRNP to 3’ss. B) HnRNPs
binding to exonic splicing silencer (ESS) and subsequent 3’ to 5’ oligomerization through exon favor exon exclusion by
blocking SR protein access to their exonic splicing enhancer (ESE). C) Intronic splicing enhancer (ISE) binding of hnRNP
interferes with intron definition and favor exon definition. D) HnRNP intron looping out. E) SR protein and hnRNPs
functional antagonism. F) Tissu-specific splicing factor tend to favor exon inclusion when bound to intronic splicing
silencer (ISS) in intron downstream of alternative exon and exclusion when bound upstream. Gray boxes = constitutive
exons; white boxes = alternative exons; 5’ = 5’ splice site; 3’ = 3’ splice site.
3. The advantage of alternative splicing as a source of ovarian cancer
biomarker
Analysis of the ovarian cancer proteome using mass spectrometry is undoubtedly the most di‐
rect approach for the identification of biomarkers that could be readily implemented in the
clinic. However, the difficulty generating specific antibodies for the large number of potential
markers generated via this approach makes marker validation very difficult. In contrast, the
validation of nucleic acid markers generated through microarray or deep-sequencing screen is
fairly simple and is often achieved by polymerase chain reaction (PCR) [34,37]. Furthermore,
the function of these potential markers can easily be verified through the knockdown of gene
expression using RNA interference (RNAi) strategies [38]. However, scoring global changes in
gene expression as markers for ovarian cancer limits the assay to ~25000 genes in the genome,
while it is estimate that the human cells contains at least >100 000 proteins. This limitation is no
longer an issue when we consider the expression of specific splice variants, the number of
which equal or exceeds the number of cellular proteins [39]. In addition, it is much easier to pre‐
dict the function of an alternative splice variant than predicting the function of a peptide mark‐
er. For examples, while the role of the well established markers CA-125 remain unclear after 25
years of research [40], one could easily predict the function of a marker by the protein domain
eliminated or included through AS as is the case of the tyrosine kinase SYK. In this case, exon
skipping remove a nuclear localization domain leading to the accumulation of protein in the
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cytoplasm, elegantly explaining the lost of nuclear function associated with cancer [38]. Pre‐
dicting the impact of AS is particularly attractive for biomarkers development when the alter‐
native exon encodes a plasma transmembrane domain or an extracellular protease cleavage
site [41]. In these cases, one would be able to predict whether the cancer associated marker
leads to an increase or decrease in the secretion of membrane anchored protein, an information
that is difficult to obtain using global gene expression profiles.
4. The challenges of detecting splicing isoforms
Examples of alternatively spliced genes are steadily accumulating in the literature for more
than 20 years and the discovery rate was greatly accelerated by recent technological advances
like transcriptome sequencing techniques.  Indeed, while early estimation of alternatively
spliced genes based on Northern-Blots and endpoint RT-PCR were around 5% of the human
genome, transcriptome sequencing revealed ASEs in 95% of the human genes with multiple in‐
trons [39]. Different techniques have different capacity to illustrate the number of ASEs (see Ta‐
ble 1) and detecting splice variants remained difficult to detect for many years, which explains
the reason they are not regularly considered as a source of biomarkers by most clinicians.
Technique Throughput Advantages Limitations
Northern-Blot Low No amplification
Several isoforms can be
detected in a single sample
Labour-intense
Large amount of RNA needed
Restricted by gel resolution
Endpoint RT-PCR Low to medium Considered as the gold
standard for validation
Results easy to analyze
Throughput is enhanced when
coupled to capillary
electrophoresis
Labour-intense if polyacrylamide
gels are used to separate PCR
products
Low quantitative range
Restricted by gel resolution
Real-time PCR Low to medium Provided already validated
data
Large quantitative range
Accurate data in fixed tissues
Custom primer design
often needed
Microarray medium Some array are commercially
available
Complex analysis
Results need PCR validation
Next generation Sequencing Medium to High Independent of genome
annotation
(Discovery of novel splicing
isoforms)
High cost prevent the use of
biological replicates
Long multi-step procedure
Complex analysis
Results need PCR validation
Table 1. Techniques used for the detection of alternative splicing
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Back in the 1980’s, splicing isoforms were mainly detected by Northern-Blot, which separate
transcripts by size [42] and estimate relative mRNA abundance using internal controls.
However, this method is difficult to adopt in a clinical setting and require a large amount of
RNA (µg), which is difficult to obtain from clinical samples. Later, the discovery of reverse
transcription and PCR amplification greatly facilitated the detection of splice variants [43].
Splicing isoform amplification is achived by using PCR primers that are designed to hybrid‐
ize to constitutive exons flanking the ASE of interest (Fig. 4A). The products are separated in
agarose gels or capillary gel electrophoresis [44] and the ratio of the long and short isoform
quantified and presented as ψ (percent of splicing index): the molarity of the long over the
sum of the long and the short isoforms (Fig. 4A). Even if competitive PCR reaction are limit‐
ed to a narrow range [43,45], endpoint PCR is still the preferred technique to detect splicing
isoforms due to the ease of use and low cost of the experiments.
The gold standard for the mRNA quantification is real-time PCR [46], which unlike stand‐
ard endpoint PCR, detects the amount of products accumulating after each cycle of amplifi‐
cation and permits accurate comparison of different samples. This type of PCR requires the
use of fluorescent probes [47] or dyes [48] that permit detection by specialized sensors. De‐
spite the accuracy of this detection method it is rarely used for the detection of splice var‐
iants due to difficulty in achieving isoform specific amplification [43,49]. Primers required
for the amplification of the short isoform need to bind to a short unique sequence created by
the exon-exon junction, which severely restrict the design (Fig. 4B). However, systematic
evaluation of isoform specific design parameters and the availability of new algorithms for
primer selection greatly facilitated the detection of ASEs from any species [49]. Indeed, uni‐
versal PCR conditions and ease of primer design makes real-time PCR reaches the point
where it can compete with high-throughput detection methods like microarray in term of
ASE coverage [49].
Microarray as a method for genome-wide expression profiling was discovered in 1995 [50],
but the use of this method to detect splice variants was reported only in 2003 [51]. It took 8
years to develop methods that could distinguish between the hybridization patterns of two
closely related transcripts and develop chips with high enough density to accommodate the
thousands of splicing isoforms [51] (Fig. 4C) Early attempts to extract splicing pattern from
expression microarrays generated high false positive rate [52]. Therefore, strategies where
developed to probe exon-exon junction (junction array) [51]. In this case, alternative exons
are defined by very low or very high signals emanating from two consecutive splice junc‐
tions [51]. Another popular strategy is to use exonic probe in addition to exon-exon junction
probe (exon/junction array) [53]. In every case, the high similarity of exon-exon junction to
favor non-specific hybridization and in some analysis procedures the information is restrict‐
ed to splicing isoform “detection” rather than true quantification [54]. The most successful
quantification of splicing isoform by microarray was achieved by relying solely on exonic
probe [54-56]. However, the success of this method was limited by its dependence on a
small set of pre-selected splice variants [53,57]. To allow the discovery of new splicing iso‐
forms, a fourth strategy that consider all putative exons (tiling array) was developed [58].
However, the high number of probe required for this methods restricted coverage to only a
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small fraction of the genome. Not surprisingly, these difficulties hampered the application
of this method for the study of ovarian cancer splicing isforms. Indeed, to date there is no
report of microarray based profiling of ovarian cancer splice variants.
In theory, the most promising approach for the detection of ovarian cancer splicing iso‐
form is the transcriptome sequencing [39]. Next generation sequencing (NGS) technology
provide massively parallel sequencing of nucleotidic sequences in miniaturized microsys‐
tem.  Several  platforms are  commercially  available  and their  unique  technology are  dis‐
cussed  elsewhere  [59,60].  The  specific  application  of  mRNA  quantification  through
sequencing  (RNA-seq)  was  demonstrated  for  different  cancer  types  (e.g.  lung  [61]  and
prostate [62]) but not ovarian cancer thus far. Encouraging development in the refinement
of the analytical pipeline to allow accurate quantification of splicing isoforms was recently
made [37,63,64]. However, the complexity of the analytical pipeline of sequencing data and
the cost of the sequencing read necessary to detect splice variants will reduce the speed by
which this  technique is  applied to the discovery of  splicing dependent biomarkers (Fig.
4D). In addition, secondary techniques like PCR will still be needed to confirm and vali‐
date the accuracy of the data generated and confirm it in a large number of clinical sam‐
ple. Indeed, the majority of the AS information in ovarian cancer are derived from PCR-
based techniques (see Table 2 and 3).
Figure 4. Methodology for splicing isoforms detection. A) Endpoint PCR. B) Real-time PCR. C) Microarray. D) Next Gen‐
eration Sequencing. Red arrows and lines refer to short isoform specific detection. Gray boxes = constitutive exons;
white boxes = alternative exons.
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Gene Technique Marker type and isoform description Reference
BRCA1/2 Endpoint
RT-PCR
Prognosis
Numerous DNA mutation inactivated BRCA1/2 function
(deletion of essential domain or protein truncation) through
aberrant splicing.
[67]
RUNX1
(AML1)
Real-time
RT-PCR
Prognosis
AML1bDel179-242 expression inversely
correlates with overall survival
[69]
KLF6 Real-time
RT-PCR
Grade
The ratio of total to full length KLF6 expression correlates with
ovarian tumor grade
[72]
TP53 Real-time
RT-PCR
Chemoresistance
p53δ expression is associated to impaired response to first line
chemotherapy
[75]
FBLN1 Endpoint
RT-PCR
Diagnosis
*The ratio of Fibulin C/D increase in ovarian tumors
[77]
SPP1 Real-time
RT-PCR
Diagnosis
*Osteopontin-c is undetectable in normal ovaries and present
in ovarian tumors
[85]
*Potential serum marker
Table 2. Ovarian cancer splicing markers discovered through single gene analysis
Number of ASEs Technique Marker type and splicing signature description Reference
48 ASEs Endpoint
RT-PCR
Diagnosis
This signature distinguishes normal ovaries from ovarian
tumors regardless of grade, stage or histotype (serous,
muscinous, endometriod, mix type)
[44]
288 ASEs Endpoint
RT-PCR
Diagnosis
This signature distinguishes normal ovaries from serous high
grade ovarian tumors.
[36]
8 ASEs Real-time
RT-PCR
Diagnosis
This cancer epithelial signature (CES) distinguishes normal
Fallopian tube epithelium tissues from ovarian epithelial
cancer cells
[84]
10 ASEs Real-time
RT-PCR
Diagnosis
This cancer stromal signature (CSS) distinguishes normal
tissues from ovarian tumors independent of the epithelial
content of the tissue compared
[84]
Table 3. Ovarian cancer splicing markers derived from high-throughput expression profiling.
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5. Example of alternative splicing based ovarian cancer biomarkers
5.1. Gene specific discovery of splicing markers
PCR-based techniques of specific genes associated with ovarian cancer revealed a number of
ovarian cancer associated splicing events. The most promising of these potential biomarkers
for diagnosis, prognosis, chemoresistance and grade biomarkers are listed in table 2 and are
further described in the text below.
BRCA1/2. The ability of DNA mutation in the hereditary gene BRCA1 and BRCA2
(BRCA1/2) to predict the risk of ovarian and breast cancer is known for decades [65,66].
However, in several instance, the clinical relevance of DNA mutation is unknown, making
the clinical management difficult to establish properly. Furthermore, the role of these muta‐
tions in varying the splicing of BRCA genes was largely ignored despite the fact that any
nucleotide changes in the splice site consensus sequences or in any AS regulatory sequence
could produce aberrant splicing isoforms. Recently, in vitro splicing assay of BRCA1/2 muta‐
tion [67], revealed that many cancer associated variants including those with unsuspected
synonymous mutations have dramatic effect on splicing. Strikingly, six of the most frequent
DNA variants representing 58,5% of BRCA1 families induced aberrant splicing profile [67].
These results, clearly demonstrate the importance of studying cancer associated splicing
since it may in many case help explain mutation that cannot be associated with changes in
protein sequence. However, the fidelity of splicing signature as a diagnostic marker as com‐
pared to DNA sequencing remains to be established.
RUNX1. Runt-related transcription factor 1 is a transcriptional regulator harboring a DNA-
binding runt homology domain (RHD). Several layers of regulation (transcription, splicing
and translation) fine-tune its tissue-specific expression [68]. RUNX1 is also known as Acute
myeloid leukemia (AML) 1 and is often found as oncogenic fusion in leukemia. Nanjundan
M and collaborators [69] report the fortuit discovery of a novel isoform that lack exon 6 as
compared to isoform AML1b during classical cloning procedure. This novel isoform, subse‐
quently named AML1bDel179-242 was found to be the dominant isoform in the majority of the
42 ovarian tumors studied. Functionally speaking, skipping of exon 6 severely abrogated the
transactivation potential of the resulting protein and inhibits its tumor suppressive func‐
tions. Interestingly, AML1bDel179-242 level was either not different from normal cell line (lung
cancer) or significantly decreased (breast cancer), suggesting that it may be an ovarian spe‐
cific marker [69]. Noneoftheless, AML1bDel179-242 expression is inversely proportional to the
survival rate of patient, suggesting is used as a prognosis marker [69]. As attractive as it
sounds, AML1bDel179-242 certainly represent an excellent potential target and marker but re‐
quired further validation in larger cohort and by independent research group.
KLF6. Kruppel-like factor (KLF) 6 is a transcription factor from the well conserved KLF gene
family implicated in differentiation, development and cell growth [70,71]. KLF6 is a suspect‐
ed tumor suppressor gene in several epithelial cancer (see [72] and reference there in). In
ovarian cancer, an increase in KLF6 isoforms was noted and correlates with the aggressivity
of the tumor in tissues (grade). One of these isoform is produced by the use of the more dis‐
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tal alt5’ ss and produce a protein version lacking the characteristic zinc finger binding do‐
main (KLF6 SV1) and act as a dominant-negative [72]. Although the technical challenges of
amplifying specific KLF6 isoforms preclude pinpointing the KLF6 SV1 as the isoform that
correlates with grade tumor, a series of in vitro and in vivo evidence making it likely [72]. It
remains to be established whether or not the full length KLF6 over KLF6 SV1 isoform ratio
could serve as a prognosis or even early marker.
TP53. The tumor suppressor gene TP53 is mutated in several solid tumors and in almost all
of the serous ovarian tumors [73]. Mutations affecting splice site of TP53 are very common
[74] and leads to a complex pattern of splicing isoforms that add up to the already complex
picture of this gatekeeper. Indeed, the point mutation IVS9-2A>G destroys the splice accept‐
or and redirect the splicing to include exon 9c. The resulting p53δ protein isoform is truncat‐
ed in the oligomerization domain and have a new stretch of 27 new residues. In a cohort of
245 ovarian samples, the expression of this isoform is significantly correlated with poor
overall survival in multivariate analyses. Moreover, patient having tumor that express p53δ
have a higher chance of early relapse after first-line chemotherapy [75]. Since isoform p53δ
doesn’t correlate with the debulking status, it suggests that expression of p53δ impair plati‐
num-based chemotherapy [75]. In respect to personalized medicine, it would be very inter‐
esting to sensitize these tumors by targeting p53δ. Thus, p53δ is not only a potential adverse
prognosis marker but could also be a promising target for a subclass of ovarian tumors.
FBLN1. Fibulin (FBLN) 1 is an extracellular matrix (ECM)-associated protein produced by
both stromal cells and epithelial cells [76]. Its presence near sites of epithelial cells locally
invading stromal boundaries suggests its implication in cell adhesion/motility (see [77] and
reference there in). Different C-terminal exons of the FBLN1 gene are alternatively spliced to
generate four isoforms. In ovarian tumors, the ratio fibulin 1C / fibulin 1D is significantly
increased compared to benign ovarian cystic sample [77]. Interestingly, the isoform ratio be‐
tween normal and benign cyst is slightly increased in cystic samples (although not signifi‐
cant). It raises the hypothesis that the ratio fibulin 1C / fibulin 1D could potentially serves as
an early diagnostic marker. Importantly, the sensitivity and specificity of fibulin splicing iso‐
forms remains to be firmly established using a panel of normal and early lesion tissues and
ultimately in patient’s serum.
SPP1. Osteopontin is a member of the small integrin-binding ligand, N-linked glycoprotein
(SIBLING) family of proteins [78]. It is an important component of the ECM that is secreted
by both cancer cells and stromal cells in the tumor microenvironment [79]. Osteopontin in‐
teracts with various integrin receptors [80,81] as well as the CD44 receptor [82] to activate
the angiogenic switch or enhance cancer cell motility [79]. The level of osteopontin is elevat‐
ed in patient’s plasma when compared to healthy controls by enzyme-linked immuno assay
(ELISA) [83]. However, the specificity (80,4%) and sensitivity (80,4%) for the detection of
early stage disease are not convincing [83]. These parameters could be increase if one takes
advantages of AS. A recent report conducted by real-time PCR indicated that the isoform
osteopontin c (excluding exon 4) is absent in normal or benign tissues but always present in
ovarian cancer samples. This is supported by our own data from microdissected normal and
cancerous ovarian cells indicating that the expression of osteopontin c comes specifically
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from ovarian epithelial cancer cells [84]. Conditioned medium overexpressing osteopontin c
stimulate proliferation of cancer cells more efficiently than either osteopontin a or b, and this
effect is revert by specific antibodies against osteopontin c [85]. Based on these data, the bio‐
marker capacity of osteopontin in patient’s blood need to be re-established using isoform-
specific methodology. As the secretion of osteopontin might be an early event [86-88], it is
tempting to speculate that osteopontin c could be an early marker.
5.2. Splicing markers generated through genome-wide expression profiling
The advent of splicing sensitive high-throughput technique opens the doors to monitor a
large number of randomly selected ASEs rather than be limited to few candidate genes (see
Table 3). The recent use of high-throughput RT-PCR by coupling PCR reaction in 384 wells
plate to capillary gel electrophoresis in 96 well Caliper station dramatically increased the
number of confirmed ovarian cancer associated splicing events. Initially, exon-exon junc‐
tions were systematically analyzed for a set of 600 cancer related genes in four different
pools of normal and cancer ovarian samples. The resulting ASEs were subsequently validat‐
ed using an independent set of 21 normal ovaries and 25 ovarian cancer samples, yielding 48
ASE markers [44]. Later on, a focus on a collection of 2168 highly curated ASEs (RefSeq
NCBI build 36) subsequently yield 288 ASEs markers using roughly the same sample set
[36]. The relatively high number of ASEs markers found coupled to the fact that several
were related to the epithelial-mesenchymal transition raised the possibility that a large frac‐
tion of the discovered events might result from difference in the cell type compared (normal
ovaries are largely composed of stromal cells where as ovarian tumors have a typical epithe‐
lial content around 75% [36]). This question was answered when 9 ovarian tumors were mi‐
crodissected to isolated the RNA from stromal (tumor microenvironment) and epithelial
cancer cells separately. A real-time PCR-based screening strategy coupled to an update ver‐
sion of RefSeq NCBI build 36 (3313 ASEs) yield a low but unambiguous set of cancer-specif‐
ic splicing isoforms, the cancer epithelial signature (CES) [84]. Surprisingly, the tumor
microenvironment appears to contain promising splicing isoforms RNA markers. Indeed,
this cancer stromal signature (CSS) might be able to diagnosis early ovarian tumors as it
clusters low malignant potential and low-grade tumors within normal ovaries and Fallopian
tube samples, although this study was performed on a low number of tissues [84].
The possibility that ovarian tumor microenvironment may be a source of splicing isoforms
markers raise interesting questions regarding the studies conducted on whole tumors. First,
some of the RNA transcripts detected may actually come from the microenvironment cells.
For exemple, fibulin and fibronectin are two ECM components known to be produced and
secreted by stromal cells. Pinpointing the cell type that produced those splicing deregulated
secreted proteins will certainly help to rationalize the complex autocrine and paracrine path‐
ways implicated in the cell to cell communication that take place into and surrounding the
ovarian tumor. Second, AS is a highly tissue-specific process, some of the splicing pattern
changes might be the reflection of the different proportion of stromal and epithelial cells of
ovarian tumors. Theoretically, those effects would be minimal when ovarian tumors of
equivalent epithelial content (typically 50-75%) are compared but maximal when normal
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ovaries (1% epithelial cells) are used as normal reference. As a consequence, prognosis
marker derived from cancer samples comparison should yield more reliable splicing mark‐
ers than diagnosis marker normalized with normal ovaries.
5.3. Alternative splicing associated protein markers
Interestingly, a number of RNA splicing isoforms markers might be amenable to detection
at the protein level using isoform-specific antibodies. Ultimately, these could serve as diag‐
nostic or prognostic tool to either directly detect the presence of cancer cells or indirectly the
protein in patient’s fluid. Indeed, the product of the genes encoding fibronectin 1, fibulin,
osteopontin, galectin 9, platelet derived growth factor A, extracellular sulfatase 2 and slit ho‐
molog 2 are all secreted in the extracellular matrix. Even some cytosolic proteins such as
utrophin and serine hydroxymethyltransferase 1 were found in patient’s serum [89]. Others
are cell surface protein (amyloid beta A4 protein, stromal interaction molecule 1, CD97, pep‐
tidyl-glycine alpha-amidating monooxygenase and chemokine-like factor) harboring an ASE
that encodes for an extracellular domain. More impressively, the exon encoding the trans‐
membrane domain of betacellulin is preferentially excluded in ovarian tumors [44], leading
to a secreted version of the protein [90]. Thus in every cases, isoform-specific antibodies
could be theoretically raised against the cancer associated isoform to ultimately serve as di‐
agnostic/prognostic tool to either detect cancer cells or detect the protein in patient’s fluid.
Inversely, the splicing isoforms of the cell surface receptor Fas and CD44 were mostly stud‐
ied at the protein level by either immunohistochemistry (IHC) or ELISA. Fas linked extracel‐
lular apoptotic signals that converge to the programmed cell death pathway through
caspase 8 and 10. Differential usage of exon 6, which encodes the single pass transmembrane
domain, results in a soluble version (sFas) and a membrane anchored version (mFas). The
level of sFas is increase in ovarian tumor of higher grade compared to low grade [91,92] and
correlates with worst prognosis for these patient [91]. Although these studies were per‐
formed in small cohort, it elegantly demonstrated that AS can produce isoforms detectable
in patient’s serum.
The glycoprotein CD44 is a cell surface receptor that binds diverse extracellular matrix li‐
gands such as hyaluronic acid, fibronectin, osteopontin, collagen and laminin [93]. The bind‐
ing of low molecular weight hyaluronan polymer promotes the motility and invasion
properties of CD44 (review in [93]). It is encoded as a 20 exons gene that exhibit extensive
AS of the extracellular domain of exons 6 to 15 (also called variable exons 1 to 10). The major
isoform present in normal epithelial [94,95] or stromal [96] ovarian cells is the shorter iso‐
form CD44s lacking all variable exons (CD44s for standard isoform). In contrast, a complex
pattern of splicing isoforms were detected in cancer tissues, including most of ovarian tu‐
mors by mean of RT-PCR [94,97,98] or by IHC using isoform specific antibodies
[95,96,99,100]. One of these splicing isoforms, the inclusion of exon v10, appears to correlate
with prognosis and is indicative of improved survival in a multivariate analysis of a 142 pa‐
tient cohort by IHC [96]. However, these findings contrast the initial study of Schroder who
found no exon v10 expression although it relies on a smaller cohort [100]. Intriguingly, in‐
clusion of exon v10 in metastatic tumors was correlated with decrease survival [96]. This ap‐
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parent discrepancy could be rationalized if the exon v10 inclusion is seen as crucial to
maintain proper cell adhesion and avoid cell detachment [101]. It remains to be determined
if any of the variable exons of CD44 could serve as biomarker at the RNA level.
6. Concluding remarks
AS dramatically increase the diversity of protein expression in human cells and therefore ex‐
ponentially increase the number of potential disease markers. However, the complexity in
detecting AS and the unclear function of the majority of splice variants greatly reduced the
rate of AS based ovarian cancer biomarkers. This trend is likely to change in the next few
years with the explosion of whole transcriptome sequencing efforts and the inevitable iden‐
tification of splice variants as byproducts of next generations’ expression profiles. The real
challenge now is to develop techniques allowing the use of splicing markers in the clinic and
prepare pathologists to this new wave. Clearly, a compelling argument is needed to drive
this drastic change in clinical practice and it will most likely be driven by the success of AS
based screens in rationally predicting secreted protein that may serve as non-invasive ovari‐
an cancer markers.
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